Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Datteln – page 44

1 785 clinical trials in Datteln, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Datteln at a glance
1 785
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 785 trials in Datteln

Open in trial search

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Miltenyi Biomedicine GmbH

Pruritus

Recruiting

Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Study of Cytarabine, Daunorubicin, and Clofarabine for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Clofarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:GBG Forschungs GmbH

Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Meniscus injury+1

Recruiting

Study on Human Cancellous Bone for Partial Meniscal Replacement in Patients with Incomplete Meniscal Loss

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Human Cancellous Bone
  • Sponsor:Dr. Sven Behrendt, Knie und Schulterchirurgie

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Datteln

What the registry says about research in the country

01 Pediatric Oncology

Innovative research focusing on lymphoma and leukemia treatments in children and adolescents, including studies on B-cell lymphomas and acute myeloid leukemia. These trials aim to improve survival rates through targeted therapies and novel treatment combinations.

  • B-cell lymphoma treatments
  • Acute lymphoblastic leukemia
  • Germ cell tumors

Advanced protocols incorporating immunotherapy and chemotherapy combinations are being evaluated for optimal treatment outcomes.

02 Neurological Conditions

Studies addressing various neurological disorders, including multiple sclerosis and rare conditions like tuberous sclerosis complex. Research focuses on testing new therapeutic approaches and evaluating long-term neuropsychological outcomes.

  • Relapsing-remitting MS
  • Myelin disorders
  • Developmental disorders

Trials emphasize early intervention strategies and comparative treatment effectiveness.

03 Neonatal Care

Critical research in preterm infant care, focusing on respiratory distress syndrome and retinopathy of prematurity. Studies evaluate new treatment approaches and preventive measures for improved outcomes.

  • Surfactant administration
  • Retinopathy prevention
  • Respiratory support

Investigations aim to establish optimal protocols for premature infant care and development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.